Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of 9-valent HPV vaccine immunogenicity and tolerability in young men and women
2012-002758-22Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2012
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by Merck & Co. Primary endpoint: Safety endpoints. Started Aug 2012; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2012-002758-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002758-22.